Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive disease pathology already drive a sizable cost burden for elderly patients (a growing population) and payers, and the impending launch of premium-priced brands will exacerbate these market conditions. Three novel subcutaneous pump therapies (ABBV-951 [AbbVie], ND-0612 [NeuroDerm / Mitsubishi], and SPN-830 [Supernus]) offer potentially transformative motor symptom benefits for advanced PD patients, while a range of novel adjunctive medications for niche populations (e.g., dyskinesia) are progressing through the pipeline. Anticipating payers’ receptivity to emerging products—some of which could be paradigm-altering—and how future coverage policies could affect patient access and neurologists’ treatment choice is crucial for drug developers entering an increasingly crowded, largely generic, and clinically complex market.
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Markets covered: United States
Primary research: Survey of 101 U.S. neurologists and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
Key drugs covered: ABBV-951, Duopa, Gocovri, Inbrija, IPX-203, Kynmobi, ND-0612, Nourianz, Nuplazid, Ongentys, Rytary, SPN-830, Xadago, all generic mainstays
Key companies: AbbVie, Acorda, Amneal, Kyowa Kirin, Mitsubishi, NeuroDerm, Sunovion, Supernus, UCB